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Abstract
The diabetes prevention paradigm envisages the application of strategies that support the maintenance of appropriate b-
cell numbers. Herein we show that overexpression of CXC chemokine ligand12 (CXCL12) considerably improves the viability
of isolated rat Langerhans islet cells and Rin-5F pancreatic b-cells after hydrogen peroxide treatment. In rat islets and wt
cells hydrogen peroxide treatment induced necrotic cell death that was mediated by the rapid and extensive activation of
poly(ADP-ribose) polymerase-1 (PARP-1). In contrast, CXCL12-overexpressing cells were protected from necrotic cell death
as a result of significantly reduced PARP-1 activity. CXCL12 downstream signalling through Akt kinase was responsible for
the reduction of PARP-1 activity which switched cell death from necrosis to apoptosis, providing increased protection to
cells from oxidative stress. Our results offer a novel aspect of the CXCL12-mediated improvement of b-cell viability which is
based on its antinecrotic action through modulation of PARP-1 activity.
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Introduction
Diabetes is a chronic metabolic disorder characterized by
hyperglycemia which results from insufficient insulin level or
unresponsiveness of target cells to insulin action. While the major
forms, type 1 (T1D) and type 2 (T2D) diabetes, have different
aetiologies, pancreatic b-cell dysfunction and death are at the core
of diabetic pathophysiology. Current strategies in diabetes
management are directed at lowering blood glucose levels and
treating the pathological consequences of diabetes rather than its
causes. Since a common feature of diabetes is a reduction in b-cell
mass, the promotion of b-cell growth and survival by therapeutic
treatments is considered as a novel approach for diabetes
management.
Advances in b-cell research have recently illuminated the
important role of CXC chemokine ligand 12 (CXCL12) in
preserving b-cell viability and regeneration. CXCL12 is a
chemokine constitutively expressed in a wide range of tissues [1].
CXCL12 mediates its function through the CXCR4 [2] and
CXCR7 [3], a specific G protein-coupled receptors. The
CXCL12/CXCR4 axis has an important and conserved role in
determining proper cell localization throughout the body and
comprises the only chemokine/chemokine receptor pair that
results in late embryonic lethality in mouse knockouts [4].
CXCL12/CXCR4 axis is also involved in many aspects of cell
survival and tissue repair and regeneration [5–9]. The latter role is
with potential interest in the management of diabetes in which the
irreversible loss of b-cell mass is an important feature. Thus,
treatment with CXCL12 protects INS-1 cells against injury
induced by serum withdrawal, thapsigargin, cytokines and
glucotoxicity [10]. RIP-SDF-1 transgenic mice expressing
CXCL12 under the control of the insulin promoter, are to some
extent protected against streptozotocin-induced diabetes, suggest-
ing that CXCL12 agonists could provide beneficial effects in the
treatment of diabetes [11]. It has been shown that CXCL12
protects and prolongs the life span of b-cells by inhibiting the
apoptotic process throughout Akt and ERK1/2 activation [12].
While it is generally assumed that in both forms of diabetes b-
cells primarily die by apoptosis [13], there is a growing evidence
that apoptosis is not the only mechanism of b-cell death. Several in
vitro studies revealed that b-cell necrosis is the primary mechanism
by which IL-1b or combination of cytokines induces b-cell death
[14,15]. In vivo studies with BB rats and Psammomys obesus rats,
model systems of T1D and T2D respectively, showed that the
majority of dead islet cells exhibit a typical necrotic morphology,
suggesting that necrosis is an important type of cell death during
disease development [16,17]. During the past decade, the
perception of necrosis as accidental cell death has been defini-
tively abandoned as it has been shown that necrosis, similar to
apoptosis, can be a highly regulated process with important
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pathophysiological and therapeutic implications [18]. One of the
most studied pathways in programmed necrosis is mediated via
poly(ADP-ribose) polymerase-1/Diphtheria toxin-like ADPribo-
syltransferases (PARP-1/ARTD1) [19]. In response to severe
DNA damage, prompt PARP-1 activation results in extensive
poly(ADP-ribosyl)ation of target proteins. As PARP-1 uses NAD+
as a substrate for this reaction, hyperproduction of poly(ADP-
ribose) polymers (PAR) leads to a severe depletion of cellular
NAD+ and ATP, with the ensuing energy failure resulting in
necrotic cell death [20]. The involvement of PARP-1 in b-cell
death is confirmed by the observation that pharmacological
inhibition or genetic deletion of PARP-1 protects animals against
the development of chemically-induced diabetes and protects
NOD mice from spontaneous diabetes development [21–23].
Bearing in mind previously established antiapoptotic effect of
CXCL12, our main goal was to explore whether CXCL12 also
protects pancreatic b-cells from hydrogen peroxide-induced
necrotic cell death and to examine the potential mechanisms
responsible for improved b-cell survival. We found that CXCL12
increases b-cell survival and redirects hydrogen peroxide-induced
cell death from the necrotic to the apoptotic pathway. Lowering of
PARP-1 activity is mediated by Akt kinase and is crucial for
prevention of necrosis.
Materials and Methods
Cell culture treatment
The Rin-5F, rat pancreatic insulinoma cell line (wt) (ATCC-
CRL-2058) and generated Rin-5F cells with a stable integrated
human gene for CXCL12 (#1) were cultivated in RPMI medium
supplemented with 10% FBS and penicillin/streptomycin (cell
culture reagents obtained from PAA Laboratories GmbH,
Pasching, Austria). The cell medium was exchanged every 72 h.
Rin-5F wt and #1 cells were treated for 1 h (unless otherwise
indicated) with 75 mM and 150 mM hydrogen peroxide, respec-
tively. These concentrations were established to correspond to
IC50 for each cell line. In some experiments, wt or #1 cells were
pretreated with 0.5 mM 3-aminobenzamidine (3AB; Sigma, Saint
Louis, MO, USA) for 30 min, 80 ng/ml of recombinant
CXCL12alpha (Sigma) for 30 min, or with 10 mM AMD3100
(Sigma) for 7 days. To inhibit Akt and ERK1/2 kinases, in some
experiments cells were treated with 20 mM Akt inhibitor VIII
(Calbiochem, San Diego, CA, USA) or with 20 mM MEK1/2
Inhibitor UO126 (Cell Signaling, Boston, MA, USA) for 1 h,
respectively.
Isolation of Lahgerhans islets from rats
Male albino 2.5-month old (weight: 200–250 g) Wistar rats were
used. The rats were kept under controlled environmental
conditions of temperature (2262uC), a 12 h light/dark cycle.
Standard food pellets and tap water were provided ad libitum. The
islet isolation technique is a slightly modified method described by
[24]. Briefly, islet isolation was performed in Hank’s balanced salt
solution (HBSS; 115 mM NaCl, 10 mM NaHCO3, 5 mM KCl,
1.2 mM NaH2PO4, 25 mM HEPES, 1.1 mM MgCl2) containing
1% (wt/vol.) bovine serum albumin (BSA, fraction V) (Sigma) and
5 mM glucose. The pancreas was cannulated by infusion a 10 mL
solution of 1.0 mg/mL collagenase in supplemented HBSS into
the common bile duct. Subsequently, the distended pancreas was
excised, transferred to flask tube and incubated at 37uC with
1.0 mg/mL of collagenase in supplemented HBSS for 20 min.
The digestion was stopped by adding cold supplemented HBSS
solution. The digest was allowed to sediment and after decanting
supernatant the digest was subjected to two successive washing
steps with supplemented HBSS and the resulting pellet was
resuspended in the same solution. Samples of resuspended pellet
were transferred to a blackened Petri dish and using a dissection
microscope and an external light source, islets were handpicked
(handpicking was repeated three times). Islets were collected and
washed in PBS before being dispersed into single cells by
mechanical shaking at 37uC for 3 min in 0.05% trypsin,
0.7 mM EDTA. The enzymatic reaction was stopped by adding
RPMI 1640 culture media and after centrifugation at 4006g for
10 min, cells were washed in PBS and placed in the appropriate
medium depending on the experimental protocol.
Ethics Statement
The protocol has been approved by the Committee for Ethical
Animal Care and Use of the Institute for Biological Research,
Belgrade, which is in accordance with the EEC Directive (86/
609/EEC) for the protection of animals used for experimental and
other scientific purposes.
MTT cell viability test
Rin-5F wt and #1 cell viability was estimated by the 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT;
Sigma, Saint Louis, MO, USA) viability assay. Rin-5F cells were
grown in 96 well plates and treated with hydrogen peroxide with
or without different pretreatments as will be indicated. After
removing the medium, 200 ml of MTT at a concentration of
0.5 mg/ml in RPMI was added to each well. After incubation for
2 h in the dark, the insoluble purple formazan products formed in
living cells were dissolved in dimethyl sulfoxide. Absorbance was
measured at 570 nm. Cell viability was expressed in percentages
after comparison with control cells that were assumed to be 100%
viable.
Islet cell viability assay
Viability of islet cells was determined by simultaneous staining
live and dead cells using a two color fluorescence staining: acridine
orange (AO) and propidium iodide (PI). Live cells stained green,
while dead cells stained red. Working solution was prepared (0.6 ml
AO from 5 mg/ml and 10 ml PI from 1 mg/ml stock solutions) in
1 ml PBS. Dye mix (25 ml) was added to cell suspension and
transferred to a microscope slide. Cells were visualized using Leica
DMLB fluorescence microscope.
LDH (lactate dehydrogenase) release assay
Cell culture media (without phenol red) obtained after
treatment of wt and #1 cells or islet cells with increasing
concentrations of hydrogen peroxide were collected, and 100 ml of
the supernatant were mixed with the same volume of staining
solution containing 54 mM calcium L-lactate hydrate (Sigma,
Saint Louis, MO, USA), 0.66 mM iodonitrotetrazolium chloride
(Sigma), 0.28 mM phenazine methosulfate (Acros Organics, Geel,
Belgium) and 1.3 mM NAD (Sigma) in 0.2 M Tris-HCl, pH 7.4.
The stain was developed during 15 min incubation in the dark,
and the absorbance was recorded at 492 nm. The percentage of
LDH release was obtained from the formula: LDH release (%) =
[(S-C)/(T-C)]x100%, where S is the LDH released in cell samples,
C is the level of enzyme released in the control sample, and T is
the total amount of enzyme obtained after cell lysis with 3% (v/v)
Triton X-100.
Immunocytochemistry
Wt and #1 Rin-5F cells grown on glass coverslips were fixed in
4% (w/v) paraformaldehyde, permeabilized with 0.5% (v/v)
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Triton X-100 in PBS and blocked with 3% (w/v) bovine serum
albumin (BSA) in PBS for 1 h. The slides were incubated with
anti-PAR mouse monoclonal antibody (H10; Alexis Biochemicals,
San Diego, CA, USA) (dilution 1:100) overnight at 4uC in PBS-
Tween 0.2% (v/v). After washing the cells in PBS-Tween 0.2%,
the slides were incubated in the dark with the fluorescent
secondary antibody (dilution: 1:100) for 2 h at room temperature,
washed with PBS-Tween 0.2%, and mounted on glass slides with
Mowiol (Calbiochem, San Diego, CA, USA). 4,6-Diamidino-2-
phenylindole (DAPI; Roche Diagnostics, Mannheim, Germany)
(0.4 mg/ml) was added to visualize DNA. Slides were mounted and
analyzed by fluorescence microscopy (Axio Observer Z1, Zeiss)
using appropriate filters.
Immunoblot analysis
Cell lysates were prepared with the ProteoJET Mammalian Cell
Lysis Reagent (Fermentas, Burlington, Canada). Twenty mg of the
cell lysate isolated from Rin-5F or islet cells or 20 mg proteins
precipitated from the cell culture medium after cell treatment were
separated by 12% SDS-polyacrylamide gel electrophoresis (SDS-
PAGE) and electroblotted onto a polyvinylidene difluoride (PVDF)
membrane. Immunoblot analysis was performed using anti-PARP-
1 (H-250; Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-
PAR (H10; Alexis Biochemicals, San Diego, CA, USA), anti-Akt
1/2/3 (H-136; Santa Cruz Biotechnology), anti-pAkt 1/2/3 (Ser-
473-R; Santa Cruz Biotechnology), anti-ERK 1/2 (K-23; Santa
Cruz Biotechnology), anti-pERK (E-4; Santa Cruz Biotechnology)
antibodies. Blots were probed with horseradish peroxidase-
conjugated secondary antibodies. Staining was performed by the
chemiluminescent technique according to the manufacturer’s
instructions (Amersham Pharmacia Biotech, Amersham, UK). If
different set of samples were run on different gels, immunoblot
analysis was performed in the same time, under the same
conditions. All membranes were exposed under the same film
and thus exposure and development did not influence the obtained
results.
Immunoprecipitation
Immunoprecipitation was carried out with cell lysates (200 mg)
obtained after lysis in 50 mM Tris 7.4, 150 mM NaCl, 2 mM
EDTA, 1% (v/v) Triton X-100, 1 mM PMSF, 1 mg/mL
aprotinin, and 1 mg/mL leupeptin (lysis buffer). Cell lysates were
incubated for 2 h on ice with 0.5 mg of anti-pAkt 1/2/3 (Ser-473-
R; Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-pERK
(E-4; Santa Cruz Biotechnology) antibodies or equal amount of
control IgG (sc-2027; Santa Cruz Biotechnology). Protein A/G-
coupled agarose beads (SC-2003; Santa Cruz Biotechnology) were
added for 2 h at 4uC under constant agitation. The beads were
pelleted and washed five times with lysis buffer. The immunopre-
cipitated proteins were resuspended in the sample buffer,
separated by SDS-PAGE and analyzed by immunoblot analysis.
PARP activity assay
PARP activity was measured in nuclear lysates of wt and #1
Rin-5F cells using a commercial colorimetric PARP Assay Kit
(Trevigen, Gaithersburg, MD, USA). Nuclear extracts were
prepared with ProteoJET Cytoplasmic and Nuclear Protein
Extraction Kit (Fermentas, Burlington, Canada) according to the
manufacturer’s instructions, except for the final lysis of nuclei that
was performed in 0.5% Triton X-100/1xPARP buffer (from the
Trevigen Kit). The PARP activity assay was performed according
to the manufacturer’s instructions and expressed as units of PARP-
1 activity.
Protein dephosphorylation with lambda phosphatase
Dephosphorylation was performed with 100 mg of Rin-5F
nuclear lysates that were incubated for 20 min at 30uC with 400
units of lambda protein phosphatase (Sigma, Saint Louis, MO,
USA) in reaction buffer supplemented with 16 MnCl2, all
provided by the manufacturer. After the incubation, the dephos-
phorylated nuclear lysates were immediately used for measuring
PARP activity.
RNA isolation and quantitative real-time PCR (RT-qPCR)
Total RNA from islet cells or Rin-5F wt and #1 cells was
extracted using the GeneJET RNA Purification Kit (Thermo
Fisher Scientific, Waltham, MA, USA). For cDNA synthesis, 1 mg
of the total RNA was treated with DNAse I and reverse-
transcribed with RevertAid First Strand cDNA Synthesis Kit
(Fermentas, Burlington, Canada) using oligo(dT) primers. For RT-
qPCR the Maxima SYBR Green/ROX qPCR Master Mix
(Fermentas) was used. mRNA levels were quantitatively deter-
mined with an ABI Prism 7000 Sequence Detection system
(Applied Biosystems, Carlsbad, CA, USA). The fragments
were amplified using the following primer sets: sense 59-
GATTCTTTGAGAGCCATGTC-39 and antisense 59-
GTCTGTTGTTGCTTTTCAGC-39 for the rat CXCL12 gene;
sense 59-ATGAACGCCAAGGTCGTGGT-39 and antisense 59-
GGGCACAGTTTGGAGTGTTG-39 for the human CXCL12
gene; sense 59-CTGACTGGTACTTTGGGAAA-39 and anti-
sense 59-GGAACACCACCATCCACAGG-39 for the rat
CXCR4 gene; sense 59-ATGTGCTGCTGTATACCCTC-39
and antisense 59-GTGATGACGACCCACAGATC-39 for the
rat CXCR7 gene; sense 59-CTGGTGGACATTGTGAAAGG-39
and antisense 59-TCTGCCTTCTGCTCAGTTTC-39 for the rat
PARP-1 gene; sense 59-AGGCAGCGTCACCTCGTTTG-39
and antisense 59-GGTTCAAATACGGCGTGCTC-39 for the
rat PARG gene; sense 59-ATGGCCCTGTGGATGCGCTT-39
and antisense 59-ACAATGCCACGCTTCTGCCG-39 for rat
insulin gene; sense 59-AGATTACTGCCCTGGCTCCT-39 and
antisense 59-ACATCTGCTGGAAGGTGGAC-39 for the rat b-
actin gene. The programme for qRT-PCR was comprised of an
initial denaturation step at 95uC for 10 min and a subsequent two-
step PCR programme at 95uC for 15 s, and 60uC for 60 s for 40
cycles. Negative controls without the template were used in all RT-
qPCR reactions. The expression levels of the target genes were
related to the averaged expression level of rat b-actin as the
housekeeping gene.
Statistical analysis
Three different samples were used and all the assays were
carried out in triplicate in every experiment. Mean and standard
error values (S.E.M.) were determined for all studied parameters.
Results were statistically analyzed by analysis of variance
(ANOVA). Duncan’s multiple range test (DMRT) was performed
to determine the significant differences among the groups.
Results
Characterization of CXCL12-overexpressing Rin-5F cells
In order to explore the beneficial effects and potential
mechanisms involved in CXCL12-induced b-cell survival, human
CXCL12 stable-transfected rat insulinoma Rin-5F cells (referred
to as #1) were used. Overexpression of CXCL12 in Rin-5F cells
induced changes in morphology and growth pattern in compar-
ison to wt Rin-5F cells. The wt cells were polygonal, exhibiting a
two-dimensional, monolayer-like growth pattern, whereas
CXCL12-transfected #1 cells were more spherical in shape,
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mainly displaying a three-dimensional, cluster-like growth pattern
(Figure 1A) [25]. The levels of expression of human CXCL12, rat
CXCL12, and CXCR4 and CXCR7 receptors in both cell lines,
as well as in rat islets were determined by RT-qPCR (Figure 1B).
In wt Rin-5F cells, endogenous CXCL12 expression was
comparable with that in stable transfectants, whereas human
CXCL12 was absent. In the #1 cells the expression of human
CXCL12 exceeded endogenous rat CXCL12 expression 170-fold.
CXCR4 expression was 2.5-fold higher in #1 than in wt cells,
pointing to the likelihood of autocrine and paracrine CXCL12
signalling in stable transfectants. The expression level of the other
CXCL12 receptor CXCR7 was 14-fold higher in #1 cells
compared to wt cells. In islet cells expression of rat CXCL12
was quite low, while the expression levels of both receptors were
dramatically higher compared to both Rin-5F cell lines (Fig. 1B).
Susceptibility of pancreatic b-cells to hydrogen peroxide
treatment
Susceptibility to ROS-induced cell death and the effect of
CXCL12 on b-cell survival were assessed after the treatment with
hydrogen peroxide. Cell viability gradually decreased with
increasing concentrations of hydrogen peroxide in both cell lines
and islet cells (Fig. 2A). As expected, islet cells were the most
sensitive to hydrogen peroxide treatment with IC50 of 45 mM.
However, Rin-5F #1 cells exhibited considerable resistance to
hydrogen peroxide treatment in comparison with wt cells, as the
IC50 for#1 cells (150 mM) was twice that for wt cells (75 mM). The
change in cell viability with time after the treatment with IC50 of
hydrogen peroxide for each cell line revealed different kinetics of
cell death in wt and #1 cells. While more than 40% of wt cells
died during the first hour of treatment, the loss of viability of #1
cells was more gradual, indicating that different mechanisms were
involved in the deaths of wt and #1 cells.
CXCL12 activates Akt and ERK1/2 in b-cells after oxidative
stress induction
Since it has been shown that CXCL12 exerts its protective
effects by activating the prosurvival Akt and ERK1/2 pathways,
we analysed the signalling pathways that are activated in #1 cells
that are growing in the presence of chronically elevated CXCL12
levels. We found that CXCL12-overexpressing #1 cells have
markedly increased levels of phosphorylated Akt (pAkt) in
comparison with wt cells, although the amount of Akt protein
was unchanged (Fig. 2B). The treatment with hydrogen peroxide
induced Akt activation in wt cells to some extent, while no
additional phosphorylation of Akt was detected in CXCL12-
overexpressing #1 cells which already possessed a high constitu-
tive level of pAkt. Also, in comparison to wt cells, CXCL12-
overexpressing #1 cells had a constitutively increased level of
pERK1/2 (Fig. 2B). These results point to potential roles of both
Akt and ERK1/2 kinases in the survival of pancreatic b-cells. The
treatments with hydrogen peroxide resulted in the activation of
ERK1/2 in both cell lines. In both cell lines, ERK1/2
phosphorylation decreased immediately after the treatment and
gradually increased thereafter. In wt cells, phosphorylation of
ERK1/2 reached a maximum at 60 min post treatment, whereas
in #1 cells the highest level of ERK1/2 activation was observed
after 120 min of treatment. The basal levels of pAkt and pERK1/
2 kinases were very low in islet cells. Hydrogen peroxide treatment
induced activation of ERK1/2 and in particular Akt kinase,
indicating that the same prosurvival mechanisms are turned on in
islet cells under the stress conditions.
Increased expression of CXCL12 induces switch in the
type of b-cell death
In order to establish whether the observed differences in kinetics
of cell death in wt and #1 cells is due to the activation of different
cell death pathways, we analysed the presence of PARP-1 cleavage
products. The cleavage pattern of PARP-1 serves as a biochemical
marker that can assist in distinguishing between apoptotic and
necrotic types of death. After treatments of wt and #1 cells with
either increasing concentrations or increasing durations of
exposure to hydrogen peroxide, the cell lysates and proteins
precipitated from the corresponding cell-growth media were
analyzed for the presence of specific PARP-1 proteolytic fragments
(Fig. 2C). In wt cells, the predominant cleavage product was the
50 kDa PARP-1 fragment, a typical marker of necrotic cell death,
although the apoptotic 89 kDa fragment was also present. In
contrast, in #1 cells, PARP-1 degradation yielded the apoptotic
fragment as the only cleavage product, which can be particularly
observed within the proteins released in growth media. The
pattern of PARP-1 proteolysis in islet cells resembled the Rin-5F
wt profile with predominant necrotic, but detectable apoptotic
PARP-1 fragment. Different forms of cell death in response to
hydrogen peroxide in wt and #1 cells were confirmed after
examining LDH release (Fig. 2D). Treatments of wt cells with
increased hydrogen peroxide concentrations were accompanied by
a rapid raise in released LDH and induction of necrosis. In
contrast, the treatment of #1 cells with IC50 of hydrogen peroxide
induced only 10% of LDH release. A substantial increase in LDH
release from #1 cells was observed only at much higher hydrogen
peroxide concentrations. Therefore, in response to oxidative stress,
wt cells died by apoptosis and necrosis, while the type of cell death
in CXCL12-overexpressing #1 cells was undoubtedly apoptosis.
Based on the LDH release, islet cells resembled the wt cells, as the
treatment with IC50 of hydrogen peroxide induced nearly 40% of
LDH release, confirming that necrosis plays important role in islet
cell death induced by hydrogen peroxide.
CXCL12 induces cell-signalling that modulates PARP-1
activity
Our next aim was to establish whether different types of cell
death that were observed in the two employed pancreatic cell lines
as well as islet cells, resulted from altered PARP-1 activity.
Immunoblot (Fig. 3A) and immunofluorescent analyses (Fig. 3B)
with antibody to poly(ADP-ribose) (PAR) polymers, which reflects
PARP activity, revealed clear differences between the poly(ADP-
ribosyl)ation levels in wt and #1 cells. The treatment with
hydrogen peroxide induced a rapid response and extensive PARP-
1 activation in wt cells. Similarly, PARP-1 was activated in
response to hydrogen peroxide treatment also in islet cells. At the
same time, the level of poly(ADP-ribosyl)ation was notably lower
in #1 cells, with only a slight increase observed during the
treatment. Immunoblot analysis (Fig. 3A) and RT-qPCR (Fig. 3C)
revealed that decreased PARP-1 activity in CXCL12-overexpress-
ing #1 cells was not the result of either lowering the PARP-1
protein level or repressing the PARP-1 gene transcription. On the
contrary, the PARP-1 mRNA level was 6-fold higher in #1 than
in wt cells under control conditions, and 1.7-fold higher after 1 h
of treatment with IC50 of hydrogen peroxide. The observed lower
level of poly(ADP-ribosyl)ation in #1 cells could also have been
due to higher PARG activity. The level of PARG mRNA was
slightly higher in #1 cells than in wt cells (1.4-fold), and could
have contributed to some extent to the observed lower level of
poly(ADP-ribosyl)ation in #1 cells (Fig. 3C).
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To test whether the increased level of CXCL12 in #1 is a
critical factor responsible for the observed change in PARP-1
activity, wt Rin-5F and islet cells were pretreated with recombi-
nant CXCL12 protein (80 ng/ml) before the treatment with
hydrogen peroxide. Immunoblot analyses with antibody to PAR
polymers revealed that the treatment with CXCL12 significantly
decreased poly(ADP-ribosyl)ation in wt and islet cells (Fig. 4A). In
addition, exogenously added CXCL12 improved the viability of
wt cells by 17% in comparison with hydrogen peroxide-treated
cells, while pretreatment with CXCL12 enhanced viability of islet
cells for 20% in respect to hydrogen peroxide treated islets
(Fig. 4B). Pharmacological inhibition of PARP-1 with 3AB
(confirmed by immunoblot analysis with anti-PAR antibody,
Fig. 4A), resulted in a 30% increase in viability of wt cells treated
with hydrogen peroxide (Fig. 4B). To test whether CXCL12
pretreatment, besides viability is able to influence also the
functionality of insulin-producing b-cells, insulin mRNA level
was measured by RT-qPCR (Fig. 4C). We found that pretreat-
Figure 1. Characterization of Rin-5F cells with a stable-transfected human CXCL12 gene. (A) Wild-type Rin-5F cells (wt) and CXCL12-
overexpressing Rin-5F cells (#1) observed with phase-contrast microscopy. (B) Messenger RNA levels of human and rat CXCL12, rat CXCR4 and CXCR7
receptors from Rin-5F wt and #1 cells and from isolated rat islets. The mRNA levels were determined by RT-qPCR and presented in the graphs
depicting the changes in mRNA levels relative to b-actin. The results are expressed as means 6 S.E.M. Means not sharing a common letter are
significantly different between groups (p,0.05).
doi:10.1371/journal.pone.0101172.g001
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ment with CXCL12 restored the level of insulin mRNA in wt cells
after hydrogen peroxide treatment and improved insulin expres-
sion in islet cells. These results suggest that modulation of PARP-1
activity might be a novel, CXCL12-mediated mechanism for
enhancing b-cell viability and functionality.
An agonistic effect of AMD3100 on the CXCL12/CXCR4
axis
AMD3100 is a CXCR4 antagonist that inhibits CXCL12
binding to the receptor and thereby blocks the downstream effects
of the CXCL12/CXCR4 axis. CXCL12-overexpressing #1 cells
were cultured for 7 days in a medium containing AMD3100.
Shorter exposure to AMD3100 did not significantly affect cell
Figure 2. Increased expression of CXCL12 improves cell viability and switches the type of cell death. (A) Viability assay of islet cells, wt
and #1 Rin-5F cells after treatment for 3 h with increasing concentrations of hydrogen peroxide or in different time points with IC50 of hydrogen
peroxide for each cell line. (B) The effect of hydrogen peroxide treatment on the protein levels of Akt kinase and phosphorylated Akt kinase (pAkt)
(top panel) and ERK1/2 kinase and phosphorylated ERK1/2 kinase (pERK1/2) (lower panel) determined by immunoblot analysis in islet cells, wt and#1
cells. (C) PARP-1 degradation pattern after treatment of islet cells, wt and #1 cells with the increasing concentrations of hydrogen peroxide or in
different time points after treatment with IC50 of hydrogen peroxide. Immunoblot analysis with anti-PARP-1 antibody was performed with cell lysates
and proteins released in cell-growth media. FL – Full length PARP-1; Ap – Apoptotic fragment of PARP-1; Nc – Necrotic fragment of PARP-1. (D) The
effect of increasing concentrations of hydrogen peroxide on cell membrane integrity estimated by LDH release in islet cells, wt and #1 cells. The
results are expressed as means 6 S.E.M.
doi:10.1371/journal.pone.0101172.g002
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viability and PARP-1 activity (results not shown). Unexpectedly,
AMD3100 had a profound effect on #1 cell viability, improving
cell survival after the hydrogen peroxide treatment by 33% in
comparison with #1 cells treated only with hydrogen peroxide
(Fig. 5A). This ligand-like, agonistic effect of AMD3100 was
further confirmed by the increased levels of pAkt and pERK
kinases observed after pretreatment of #1 cells with AMD3100
(Fig. 5B). Interestingly, AMD3100 induced complete inhibition of
PARP-1 activity in both control and hydrogen peroxide treated
#1 cells (Fig. 5B), suggesting once again that the activation of the
CXCL12 receptors has a pronounced diminishing effect on
PARP-1 activity.
Involvement of downstream kinases in CXCL12-mediated
modulation of PARP-1 activity
Since a direct interaction of PARP-1 and kinase is a prerequisite
for PARP-1 phosphorylation and change in its enzymatic activity,
an immunoprecipitation assay was performed with anti-pAkt and
anti-pERK1/2 antibodies in order to check for potential kinase(s)-
PARP-1 protein-protein interactions. The obtained immunopre-
cipitates were subsequently probed with anti-PARP-1 antibody.
Under physiological conditions, pAkt interacted with PARP-1 in
both cell lines (Fig. 6A). In #1 cells this interaction persisted after
the treatment of cells with hydrogen peroxide, while in wt cells, the
oxidative insult of cells resulted in the complete disappearance of
pAkt-PARP-1 interaction. No interaction between pERK1/2 and
PARP-1 was detected in wt cells, neither under basal conditions
nor after the hydrogen peroxide treatment. However, pERK1/2-
PARP-1 interaction was detected under basal conditions in
CXCL12-overexpressing #1 cells, while the hydrogen peroxide
treatment resulted in a loss of pERK1/2-PARP-1 interaction
(Fig. 6A). Thus, in wt cells PARP-1 activity can be modulated only
in the basal state through phosphorylation by Akt. In #1 cells,
both kinases can influence the activity of PARP-1 as follows: in the
basal state PARP-1 can be phosphorylated with Akt and/or
ERK1/2 independently, while modulation of PARP-1 activity
during oxidative stress is solely the result of Akt activity.
To test if pAkt and pERK1/2 could influence the activity of
PARP-1, both cell lines were pretreated with specific Akt (Akt
inhibitor VIII) or MEK1/2 (UO126) inhibitors, and the corre-
sponding cell lysates were probed with antibody to anti-PAR
polymers (Fig. 6B). With increased concentration of Akt inhibitor
VIII, the level of auto-poly(ADP-ribosyl)ation was augmented,
suggesting that the Akt-mediated phosphorylation of PARP-1 led
to a decrease in PARP-1 activity. In accordance with the absence
of PARP-1-pERK1/2 interaction, the presence of MEK 1/2
inhibitor did not influence PARP-1 activity in wt cells (Fig. 6B).
On the other hand, increasing concentrations of MEK1/2
inhibitor led to slight diminishment in the level of auto-
poly(ADP-ribosyl)ation in #1 cells, suggesting that the phosphor-
ylation of PARP-1 by ERK1/2 is responsible for the increase in
PARP-1 enzymatic activity.
In order to estimate the overall effect of PARP-1 phosphory-
lation on its activity, control and hydrogen peroxide-
treated CXCL12-overexpressing #1 cells were pretreated with
lambda-phosphatase in order to induce protein dephosphorylation
(Fig. 6C). Lambda-phosphatase dephosphorylation decreased
PARP-1 activity by 30% in control, and by 15% in hydrogen
peroxide-treated #1 cells, as measured by the PARP-1 activity
assay, indicating that the aggregate effect of PARP-1 phosphor-
ylation is promotion of PARP-1 enzymatic activity. Next, control
and hydrogen peroxide-treated #1 cells were treated either with
Akt or MEK1/2 inhibitors, after which PARP-1 activity was
measured (Fig. 6D). Parallel to this, an immunoprecipitation assay
was performed in order to inspect the existence of Akt-PARP-1
and ERK1/2-PARP-1 interactions, in the presence of kinase-
specific inhibitors (Fig. 6D). Though treatment with Akt inhibitor
promoted loss of pAkt-PARP-1 interaction it did not alter PARP-1
activity in control #1 cells. However, the pretreatment of #1 cells
with Akt inhibitor before exposure to hydrogen peroxide resulted
in further activation of PARP-1, in comparison with #1 cells
treated only with hydrogen peroxide. Although we confirmed loss
of pERK1/2-PARP-1 interaction after treatment with MEK1/2
inhibitor, (Fig. 6D, inset), the PARP-1 activity assay did not show
any significant changes of PARP-1 activity as a consequence of
ERK 1/2 inhibition in control #1 cells. In addition, inhibition of
ERK1/2 did not influence the activity of PARP-1 after the
hydrogen peroxide treatment, as expected. It can be concluded
that the phosphorylation of PARP-1 mediated by Akt results in the
inhibition of PARP-1 activity in #1 cells. While ERK1/2 was
highly active in #1 cells, its influence on PARP-1 enzymatic
activity was limited.
Discussion
Promotion of b-cell survival is a rational therapeutic approach
to prevent onset or treat diabetes. Based on protection of b-cells
against different types of injury, it has been suggested that
chemokine CXCL12 or its agonists could provide beneficial effects
in diabetes treatment [10,11]. The protective effects of CXCL12
have been attributed to its antiapoptotic actions. As necrosis
emerges as an important mechanism of b-cell loss in diabetes, we
explored the beneficial effects of CXCL12 on necrotic b-cell
death. Treatment with hydrogen peroxide in Rin-5F wt and islet
cells was accompanied predominantly with necrosis (Fig. 2). We
found that CXCL12 present in excess amounts, either chronically
as in #1 cells or transiently after treatment of wt cells with
recombinant CXCL12, is responsible for the improvement of b-
cell survival after exposure to hydrogen peroxide. More impor-
tantly, the same prosurvival effect was observed after pretreatment
of isolated pancreatic islet cells with recombinant CXCL12.
Our results suggest that CXCL12 downstream signalling
induces diminishment of PARP-1 activity, rendering the cells
more resilient to the hydrogen peroxide treatment and switches
cell death from necrosis, as in wt cells, to physiological cell death
apoptosis detected in CXCL12-overexpressing #1 cells. Also,
treatment of #1 cells with AMD3100 resulted in inhibition of
PARP-1 activity and in increased viability after hydrogen peroxide
treatment. Although AMD3100 is known as a specific antagonist
of CXCR4 [26,27], there are some studies pointing to partial
agonistic effects of AMD3100 [28] most likely through interaction
Figure 3. Overexpression of CXCL12 induces a diminishment of PARP-1 activity. Poly(ADP-ribosyl)ation level in islet cells, wt and #1 cells
after treatment with IC50 hydrogen peroxide determined by immunoblot (A, top panel) and by immunofluorescent analysis in wt and #1 cells (B)
with anti-PAR antibody. The PARP-1 protein level in wt and #1 cells was determined by immunoblot analysis with anti-PARP-1 antibody (A, lower
panel). (C) mRNA levels of PARP-1 and PARG in wt and #1 control cells and cells after 1 h of hydrogen peroxide treatment followed by 5 h of
recovery in the cell culture media. The mRNA levels were determined by RT-qPCR and presented in the graphs depicting the changes in mRNA levels
relative to b-actin. The results are expressed as means 6 S.E.M. Means not sharing a common letter are significantly different between groups (p,
0.05).
doi:10.1371/journal.pone.0101172.g003
CXCL12 Prevents Necrosis by Lowering PARP-1 Activity
PLOS ONE | www.plosone.org 8 July 2014 | Volume 9 | Issue 7 | e101172
Figure 4. Pretreatment of b-cells with recombinant CXCL12 improves viability and induces a decrease in PARP-1 activity. (A)
Poly(ADP-ribosyl)ation level of wt cells and wt cells pretreated either with recombinant CXCL12 (80 ng/ml) or with 3AB (0.5 mM) before exposure to
hydrogen peroxide, determined by immunoblot analysis with anti-PAR antibody. Poly(ADP-ribosyl)ation level of islet cells before and after treatment
with hydrogen peroxide and islet cells pretreated with recombinant CXCL12 (80 ng/ml) (A, top panel). The PARP-1 protein level in these samples was
determined by immunoblot analysis with anti-PARP-1 antibody (A, lower panel). (B) Viability assay of control and wt cells treated with IC50 hydrogen
peroxide and wt cells pretreated with recombinant CXCL12 or 3AB before treatment with hydrogen peroxide. Viability assay of islet cells before and
after treatment with hydrogen peroxide and islet cells pretreated with recombinant CXCL12 (80 ng/ml). (C) mRNA levels of insulin wt Rin-5F and islet
cells with or without pretreatment with recombinant CXCL12 before hydrogen peroxide treatment. The cells were exposed to hydrogen peroxide for
1 h, followed by 5 h of recovery in the cell culture media. The mRNA levels were determined by RT-qPCR and presented in the graphs depicting the
changes in mRNA levels relative to b-actin. The results are expressed as means 6 S.E.M. Means not sharing a common letter are significantly different
between groups (p,0.05).
doi:10.1371/journal.pone.0101172.g004
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with alternative CXCL12 receptor, CXCR7 [29]. The activation
of CXCR7 by its physiological ligands results in the activation of
Akt [30] and ERK kinase [31], and enhances survival and
proliferation of myeloma cells in vitro [32,33], similar pattern of
events that we observed after the AMD3100 treatment. Regardless
of the cause of the AMD3100-induced receptor(s) activation, our
overall finding is that stimulation of CXCL12 receptor(s) resulted
in inhibition of PARP-1 activity.
Recently, several kinases were identified as new regulators of
PARP-1 activity. Depending on the kinase involved, the
phosphorylation of PARP-1 can result in either augmentation or
inhibition of its enzymatic activity. Protein kinase C (PKC) [34]
and DNA-dependent protein kinase (DNA-PK) [35] phosphory-
late and inhibit PARP-1 activity, while PARP-1 phosphorylation
mediated by 59 AMP-activated protein kinase (AMPK) [36],
ERK1/2 [37] and c-Jun N-terminal kinase (JNK) [38] promote
the catalytic activity of PARP-1. The prosurvival effect of
CXCL12 was proposed to be through the activation of Akt and
ERK kinases [12]. In our experimental setup, overexpression of
CXCL12 increased the level of both pAkt and pERK1/2 in #1
cells when compared to wt cells, pointing to a potential role of
both signalling pathways in the increased survival rate of
pancreatic b-cells. Immunoprecipitation experiments revealed
that both CXCL12-downstream kinases Akt and ERK1/2 can
contribute to a change in PARP-1 activity in CXCL12-overex-
pressing #1 cells. Interestingly, we observed a complete loss of
pERK1/2-PARP-1 interaction after the treatment of #1 cells with
hydrogen peroxide, while the interaction of pAkt and PARP-1
persisted after the insult. In wt cells, PARP-1 was found to interact
only with Akt kinase under basal conditions. Although the results
we obtained after complete protein dephosphorylation using
lambda-phosphatase suggest that the sum effect of PARP-1
phosphorylation in #1 cells is promotion of its activity,
experiments with the specific Akt inhibitor unambiguously showed
that the result of Akt-PARP-1 interaction is inhibition of PARP-1
activity. Although there is no literature data about Akt-mediated
PARP-1 phosphorylation, a similar effect on PARP-1 activation in
LPS-stimulated macrophages was observed after the incubation of
cells in the presence of the PI3K inhibitor LY294002 [39]. Using
MEK1/2 inhibitor, we found that the ERK1/2-mediated
phosphorylation of PARP-1 induces statistically insignificant
increase in PARP-1 activity under both conditions.
Based on these findings we proposed a working model (Fig. 7)
which additionally explains CXCL12-mediated improvement of
b-cell viability. According to this, the interaction of pAkt with
PARP-1 and its subsequent phosphorylation has a crucial impact
on maintaining low PARP-1 activity. In response to severe DNA
damage, the loss of pAkt-PARP-1 interaction lifts the suppression
on PARP-1 enzymatic activity, allowing for extensive PARP-1
auto-poly(ADP-ribosyl)ation, NAD+ and ATP depletion and
results in necrotic cell death. The excess of CXCL12 present in
#1 cells allows for the activation of downstream signalling kinases
(Akt and ERK1/2) through paracrine and autocrine actions. The
subsequent phosphorylation status of PARP-1 after the hydrogen
peroxide treatment that is mediated by both kinases, contributes to
the prevention of hyperactivation of PARP-1 in #1 cells. Namely,
the increased phosphorylation of Akt kinase induces pAkt-PARP-1
interaction which persists even after an insult has passed,
maintaining a continual partial suppression of PARP-1 activity.
The prevention of PARP-1 hyperactivation in the presence of
CXCL12 is also assisted by the loss of the PARP-1 stimulating
interaction with pERK. The proposed modulation of PARP-1
activity by CXCL12 could be a novel mechanism that additionally
explains the prosurvival effects of CXCL12. Although pharmaco-
logical inhibitors of PARP-1 improve b-cell resistance against
various injury agents [21], the complete inhibition of this enzyme
with so many different roles in cell metabolism could be
deleterious. CXCL12-mediated reduction of PARP-1 activity, in
contrast to its total inhibition, would allow the repair of damaged
DNA and basic transcriptional activity of PARP-1 in cells exposed
to stress. At the same time, if DNA damage is too widespread, it
would allow apoptosis since PARP-1 hyperactivation, energy
depletion and activation of necrotic cell death is prevented (Fig. 7).
Akt kinase is well known for its antiapoptotic prosurvival effects.
According to our results, it also possesses an antinecrotic potential.
It was previously reported that the activation of Akt inhibits
ceramide-induced cell death with a necrotic morphology in glioma
cells [40]. Also, the expression of active Akt kinase protects against
Figure 5. Agonistic effect of AMD3100 on CXCL12-overexpressing Rin-5F cells. (A) Viability assay of control and hydrogen peroxide-treated
#1 cells grown in the absence or in the presence of AMD3100. The results are expressed as means 6 S.E.M. Means not sharing a common letter are
significantly different between groups (p,0.05). (B) The effects of AMD3100 treatment on the protein levels of Akt and ERK1/2 kinases and
phosphorylated Akt (pAkt) and ERK1/2 kinases (pERK) (left panel), and on the poly(ADP-ribosyl)ation level and PARP-1 presence (right panel)
determined by immunoblot analysis in control and hydrogen peroxide-treated #1 cells grown in the absence or in the presence of AMD3100.
doi:10.1371/journal.pone.0101172.g005
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ischemia-reperfusion-induced necrosis in rat liver and cardiomy-
ocytes [41,42], as well as against nephrotoxicant-induced necrosis
in renal proximal tubule cells [43]. Although the mechanism of the
Akt-mediated antinecrotic effects was not established, it was shown
that Akt activation protects against necrosis by maintaining
intracellular ATP levels [43,44], implying a potential role of
PARP-1 in this process. It is possible that the Akt-mediated
inhibition of PARP-1 activity and thereby maintenance of ATP
levels in the cell, the mechanism we propose as an antinecrotic
effect in b-cells, is a common mechanism in Akt-mediated
protection against non-apoptotic cell death.
Recently, Liu and co-workers postulated a feed-back loop
between CXCL12 secretion from injured pancreatic b-cells and
glucagon-like peptide-1 (GLP-1) production in a-cells that induces
the growth and survival of b-cells [10] and trans-differentiation of
a-cells into new b-cells [45]. It was shown that GLP-1, besides its
antiapoptotic properties, has the potential to protect pancreatic b-
cells against necrotic cell death induced by cytokines, and that
these protective effects require the activation of Akt kinase [46]. In
the present study, CXCL12 was shown to protect pancreatic b-
cells from necrotic cell death by diminishing PARP-1 activity in an
Akt-dependent manner. GLP-1 is already in use as a therapeutic
agent in T2D patients because of its effect on glucose metabolism.
Treatment with a combination of GLP-1 and CXCL12 would not
only stimulate insulin secretion, but could also exert a direct effect
on pancreatic b-cells, enhancing their mass and promoting their
survival. Aside from its potential to stimulate b-cell regeneration
and prevent apoptosis, capability of CXCL12 to prevent
pancreatic b-cells from entering the necrotic cell death by
modulating PARP-1 activity, places chemokine CXCL12 in the
focal point of developing strategies for diabetes treatment.
In conclusion, in this paper we shed light on additional
mechanisms besides previously established, which could further
explain the increased viability of rat pancreatic islet cells as a result
Figure 6. Modulation of PARP-1 activity mediated by Akt and ERK1/2 kinases. (A) Immunoprecipitation of pAkt and pERK1/2 in lysates of
control and hydrogen peroxide-treated wt and #1 cells. Immunoprecipitation was performed with anti-pAkt, anti-pERK1/2 and control IgG
antibodies, and the obtained immunoprecipitates were probed with anti-PARP-1 antibody. (B) The effect of Akt inhibitor VIII (left panel) and MEK1/2
inhibitor (UO126) (right panel) on the level of poly(ADP-ribosyl)ation in control wt and #1 cells using immunoblot analysis with anti-PAR antibody
(lower panel). The inhibition of kinases was estimated by immunoblot analysis with anti-pAkt, anti-pERK1/2, anti-Akt and anti-ERK1/2 antibodies (top
panel). (C) PARP-1 activity assay performed with nuclear lysates from control and hydrogen peroxide-treated #1 cells and lysates that were
dephosphorylated by lambda-phosphatase. (D) PARP-1 activity assay performed with nuclear lysates from control and hydrogen peroxide-treated#1
cells, without pretreatment or pretreated with Akt inhibitor VIII or MEK1/2 inhibitor (UO126). Every bar graph is accompanied by a corresponding
immunoprecipitate; Immunoprecipitation was performed with anti-pAkt and/or anti-pERK1/2 antibodies, and the obtained immunoprecipitates were
probed with anti-PARP-1 antibody. The results are expressed as means 6 S.E.M. Means not sharing a common letter are significantly different
between groups (p,0.05).
doi:10.1371/journal.pone.0101172.g006
Figure 7. Antinecrotic effects of CXCL12 in pancreatic b-cells. During the basal conditions in wt Rin-5F cells, PARP-1 interacts with activated
pAkt. This interaction allows for PARP-1 phosphorylation that results in PARP-1 partial inhibition. In the increased presence of CXCL12 (#1) activated
kinases, pAkt and pERK1/2 are found to be PARP-1 interacting partners with no additional influence on its enzymatic activity. In contrast, during the
stress conditions and in response to severe DNA damage in wt cells, the loss of pAkt-PARP-1 interaction lifts the suppression on PARP-1 enzymatic
activity, allowing for extensive PARP-1 auto-poly(ADP-ribosyl)ation, NAD+ and ATP depletion and final necrotic cell death. The excess of CXCL12 in#1
cells allows for the increased phosphorylation of Akt kinase and pAkt-PARP-1 interaction. This interaction persists even after an insult has passed,
maintaining a continual partial suppression of overactivated PARP-1 that results in moderately active PARP-1. In this scenario, cellular energy
depletion has been prevented and switch from the necrotic to the apoptotic death has been secured by pAkt-induced prevention of PARP-1
overactivation. With the fine-tuned suppression of overactivated PARP-1 in cell under the stress, cell still operates with the active PARP-1 that is
essential player in many cellular processes.
doi:10.1371/journal.pone.0101172.g007
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of CXCL12 signaling. We showed that chemokine CXCL12
improves pancreatic b-cell and islet cells survival after hydrogen
peroxide treatment and if the damage is too severe, switches cell
death from necrotic to apoptotic. We found that the observed
prevention of necrosis results from reduced PARP-1 activity and
that diminishment of PARP-1 activity is mostly mediated by its
phosphorylation via activated Akt kinase. Crosstalk between
PARP-1 and Akt kinase could explain fine-tuned modulation of
PARP-1 activity by CXCL12 and additionally clarify the
prosurvival, in particular antinecrotic effects of CXCL12 on
pancreatic b-cells. We believe that the antinecrotic effect of
CXCL12 is particularly important in diabetes as it prevents the
generation of an additional pro-inflammatory burden resulting
from b-cells proceeding along the necrotic pathway.
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